← Back to Search
Evidence Of Early Ovarian Aging In Fragile X Premutation Carriers.
C. Welt, P. C. Smith, A. E. Taylor
Published 2004 · Medicine, Biology
Save to my Library
Download PDFAnalyze on Scholarcy
Up to 28% of female fragile X premutation carriers develop premature ovarian failure. To test the hypothesis that fragile X premutation carriers with ovulatory menstrual cycles exhibit hormone changes characteristic of early ovarian aging, 11 regularly cycling fragile X premutation carriers, 24-41 yr old (34.5 +/- 5.7 yr, mean +/- sd), drew daily blood samples across one menstrual cycle. LH, FSH, estradiol, progesterone (P4), inhibin A, and inhibin B levels were compared with levels in 22 age-matched, regularly cycling women, 23-41 yr old (34.6 +/- 5.8 yr), at each cycle stage. Total cycle (26.1 +/- 1.0 vs. 28.2 +/- 0.4 d; P < 0.05) and follicular phase length (12.9 +/- 0.8 vs. 14.5 +/- 0.4 d; P < 0.05) were decreased in fragile X premutation carriers compared with age-matched controls, whereas luteal phase length was similar (13.2 +/- 0.5 vs. 13.7 +/- 0.3 d; P = not significant). FSH was elevated across the follicular (21.9 +/- 3.5 vs. 11.2 +/- 0.5 IU/liter; P < 0.001) and luteal phases (14.6 +/- 3.9 vs. 7.9 +/- 0.5 IU/liter; P < 0.05) in fragile X premutation carriers compared with age-matched controls. Inhibin B in the follicular phase (77 +/- 11 vs. 104 +/- 6 pg/ml; P < 0.05) and inhibin A (3.4 +/- 0.7 vs. 5.8 +/- 0.5 IU/ml; P < 0.01) and P4 [7.3 +/- 1.0 vs. 10.1 +/- 0.7 ng/ml (23.2 +/- 3.0 vs. 32.1 +/- 2.3 nmol/liter); P < 0.05] in the luteal phase were decreased in fragile X premutation carriers compared with age-matched controls, whereas there was no difference in estradiol or LH. In summary, despite regular ovulatory cycles, FSH was increased in fragile X premutation carriers compared with age-matched controls. The increased FSH was accompanied by decreased inhibin B in the follicular phase and inhibin A and P4 in the luteal phase. These hormonal changes suggest that fragile X premutation carriers exhibit early ovarian aging despite regular menstrual cycles. Early ovarian aging in fragile X premutation carriers likely results from decreased follicle number and function, as reflected by lower inhibin B, inhibin A, and P4 levels.
This paper references
A randomized, controlled trial of estradiol replacement therapy in women with hypergonadotropic amenorrhea.
A. E. Taylor (1996)
Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome
I. Oberlé (1991)
Prevalence and phenotype consequence of FRAXA and FRAXE alleles in a large, ethnically diverse, special education-needs population.
D. Crawford (1999)
Clinical involvement and protein expression in individuals with the FMR1 premutation.
F. Tassone (2000)
The role of size, sequence and haplotype in the stability of FRAXA and FRAXE alleles during transmission.
A. Murray (1997)
The physiology and pathophysiology of inhibin, activin and follistatin in female reproduction
C. Welt (2002)
Tissue specific expression of FMR–1 provides evidence for a functional role in fragile X syndrome
H. Hinds (1993)
The biologic activity of a potent analogue of gonadotropin-releasing hormone in normal and hypogonadotropic men.
W. Crowley (1980)
Differential regulation of inhibin A and inhibin B by luteinizing hormone, follicle-stimulating hormone, and stage of follicle development.
C. Welt (2001)
Obstetrical and gynecological complications in fragile X carriers: a multicenter study.
C. Schwartz (1994)
Fragile X premutation is a significant risk factor for premature ovarian failure: the International Collaborative POF in Fragile X study--preliminary data.
D. Allingham-Hawkins (1999)
Inhibin A and inhibin B responses to gonadotropin withdrawal depends on stage of follicle development.
C. Welt (1999)
Assessment of ovarian reserve - is there a role for ovarian biopsy?
A. Lass (2001)
Exaggerated Free α-Subunit Levels during Pulsatile Gonadotropin-Releasing Hormone Replacement in Women with Idiopathic Hypogonadotropic Hypogonadism1
H. Lavoie (1998)
Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome
A. Verkerk (1991)
FRAXA premutation associated with premature ovarian failure.
Â. Vianna-Morgante (1996)
Twinning and premature ovarian failure in premutation fragile X carriers.
Â. Vianna-Morgante (1999)
Menstrual disorders and endocrine profiles in fragile X carriers prior to 40 years of age: a pilot study.
D. D. Braat (1999)
Increased serum FSH in female fragile X premutation carriers with either regular menstrual cycles or on oral contraceptives.
R. D. Hundscheid (2001)
Absence of expression of the FMR-1 gene in fragile X syndrome
M. Pieretti (1991)
Female reproductive aging is marked by decreased secretion of dimeric inhibin.
C. Welt (1999)
New insights into fragile X syndrome: from molecules to neurobehaviors.
P. Jin (2003)
A comparison of 13 different immunometric assay kits for gonadotropins: implications for clinical investigation.
A. E. Taylor (1994)
Serum concentrations of follicle stimulating hormone may predict premature ovarian failure in FRAXA premutation women.
A. Murray (1999)
Expansion of the fragile X CGG repeat in females with premutation or intermediate alleles.
S. Nolin (2003)
Incidence of Premature Ovarian Failure
C. Coulam (1986)
The endocrinology of dizygotic twinning in the human
C. B. Lambalk (1998)
Heterozygous fragile X female: historical, physical, cognitive, and cytogenetic features.
A. Cronister (1991)
The female and the fragile X. A study of 144 obligate female carriers.
J. P. Fryns (1986)
DNA methylation represses FMR-1 transcription in fragile X syndrome.
J. Sutcliffe (1992)
The effect of age on the cyclical patterns of plasma LH, FSH, oestradiol and progesterone in women with regular menstrual cycles.
S. Lee (1988)
Follicular Depletion During the Menopausal Transition: Evidence for Accelerated Loss and Ultimate Exhaustion*
S. Richardson (1987)
Premature ovarian failure (POF) and fragile X premutation females: from POF to to fragile X carrier identification, from fragile X carrier diagnosis to POF association data.
M. L. Uzielli (1999)
Relatively low levels of dimeric inhibin circulate in men and women with polycystic ovarian syndrome using a specific two-site enzyme-linked immunosorbent assay.
G. Lambert-Messerlian (1994)
Decreased inhibin tone and increased activin A secretion characterize reproductive aging in women.
N. Santoro (1999)
Net increase in stimulatory input resulting from a decrease in inhibin B and an increase in activin A may contribute in part to the rise in follicular phase follicle-stimulating hormone of aging cycling women.
N. Reame (1998)
Reproductive and menstrual history of females with fragile X expansions
A. Murray (2000)
Survey of the fragile X syndrome and the fragile X E syndrome in a special education needs population.
K. L. Meadows (1996)
Quantitative morphological investigations of the follicular system in women; variations at different ages.
E. Block (1952)
Prevalence of carriers of premutation-size alleles of the FMRI gene--and implications for the population genetics of the fragile X syndrome.
F. Rousseau (1995)
Dizygous twinning and premature menopause in fragile X syndrome
G. Turner (1994)
Inhibin B in males with gonadotropin-releasing hormone (GnRH) deficiency: changes in serum concentration after shortterm physiologic GnRH replacement--a clinical research center study.
S. Seminara (1996)
Age-related changes of the population of human ovarian follicles: increase in the disappearance rate of non-growing and early-growing follicles in aging women.
Alain Gougeon (1994)
Serum Inhibins A and B fall differentially as FSH rises in perimenopausal women
Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome.
F. Tassone (2000)
Characterization of the physiological pattern of episodic gonadotropin secretion throughout the human menstrual cycle.
M. Filicori (1986)
Confirmation of early menopause in fragile X carriers.
M. Partington (1996)
Antral follicle counts by transvaginal ultrasonography are related to age in women with proven natural fertility.
G. Scheffer (1999)
Neuroendocrine regulation of the corpus luteum in the human. Evidence for pulsatile progesterone secretion.
M. Filicori (1984)
Decreased inhibin B secretion is associated with the monotropic FSH rise in older, ovulatory women: a study of serum and follicular fluid levels of dimeric inhibin A and B in spontaneous menstrual cycles.
N. Klein (1996)
Studies of FRAXA and FRAXE in women with premature ovarian failure.
A. Murray (1998)
Variation of the CGG repeat at the fragile X site results in genetic instability: Resolution of the Sherman paradox
Y. Fu (1991)
Familial transmission of the FMR1 CGG repeat.
S. Nolin (1996)
Tissue-specific expression of a FMR1/β-galactosidase fusion gene in transgenic mice
M. Hergersberg (1995)
Differential regulation of inhibin B and inhibin a by follicle-stimulating hormone and local growth factors in human granulosa cells from small antral follicles.
C. Welt (2001)
Reduced FMRP and increased FMR1 transcription is proportionally associated with CGG repeat number in intermediate-length and premutation carriers.
A. Kenneson (2001)
Premature ovarian failure: an update.
J. Anasti (1998)
This paper is referenced by
Fragile X Syndrome: The FMR1 CGG Repeat Distribution Among World Populations
E. Peprah (2012)
Molecular Characterization of FMR1 Gene by TP-PCR in Women of Reproductive Age and Women with Premature Ovarian Insufficiency
Deepika Delsa Dean (2017)
Molecular mechanisms of fragile X syndrome: a twenty-year perspective.
Michael R Santoro (2012)
Aging of the human ovary and testis
A. Perheentupa (2009)
Impact of hysterectomy and levonorgestrel-releasing intrauterine system on ovarian function , bone and sexual health in menorrhagic patients
K. Halmesmäki (2007)
Correlation of triple repeats on the FMR1 (fragile X) gene to ovarian reserve: A new infertility test?
N. Gleicher (2009)
Are ovarian response and pregnancy rates similar in selected FMR1 premutated and mutated patients undergoing preimplantation genetic testing?
N. Ranisavljevic (2020)
The fragile X continuum: new advances and perspectives.
K. Cornish (2008)
Unstable mutations in the FMR1 gene and the phenotypes.
D. Loesch (2012)
One world, one woman: a transformational leader's approach to primary ovarian insufficiency
L. Nelson (2011)
Menopause and Ovarian Reserve: Genetic and Clinical Aspects
J. van Disseldorp (2010)
Fragile X for the obstetrician and gynecologist
Aimee Seungdamrong (2008)
One world, one woman: a kyosei approach to primary ovarian insufficiency.
L. Nelson (2011)
Genetic studies to identify genes underlying menopausal age.
H. Kok (2005)
Genetics of primary ovarian insufficiency
R. Rossetti (2017)
ANALIZA OVARIJSKE REZERVE PACIJENTICA LIJEČENIH POSTUPCIMA MEDICINSKI POTPOMOGNUTE OPLODNJE NA ZAVODU ZA GINEKOLOŠKU ENDOKRINOLOGIJU I HUMANU REPRODUKCIJU, KLINIKE ZA ŽENSKE BOLESTI I PORODE KBC-a SPLIT
Zdenka Palčić (2017)
The Clinical Phenotype of the Fragile X Syndrome and Related Disorders
G. Neri (2017)
Clinical Neurological Phenotype of FXTAS
M. Leehey (2010)
Fragile X‐associated primary ovarian insufficiency: evidence for additional genetic contributions to severity
J. Hunter (2008)
Fertility preservation for genetic diseases leading to premature ovarian insufficiency (POI)
Antonio La Marca (2021)
Top-down or bottom-up: Contrasting perspectives on psychiatric diagnoses
W. Verhoeven (2008)
Fragile X Clinical Features and Neurobiology
M. J. Leigh (2013)
Acceptance of fragile X premutation genetic screening in women with ovarian dysfunction.
L. Pastore (2006)
Repeat-mediated genetic and epigenetic changes at the FMR1 locus in the Fragile X-related disorders
K. Usdin (2014)
Contemporary genetic technologies and female reproduction
B.C.J.M. Fauser (2011)
Current understanding of ovarian aging
Q. Li (2012)
The FMR1 gene, infertility, and reproductive decision-making: a review
L. Pastore (2014)
Prognostic dilemmas and genetic counseling for prenatally detected fragile X gene expansions
B. Finucane (2017)
Study of the Genetic Etiology of Primary Ovarian Insufficiency: FMR1 Gene
M. Barasoain (2016)
Molecular screening of FMR 1 mutation among autism patients in China O riginal article
X. Wang (2006)
Fragile X premutation in women: recognizing the health challenges beyond primary ovarian insufficiency
L. Hoyos (2016)
Is FMR1 CGG repeat length a predictor of in vitro fertilization stimulation response or outcome?
N. Banks (2016)See more